Literature DB >> 18227709

Routine positron emission tomography and positron emission tomography/computed tomography in melanoma staging with positive sentinel node biopsy is of limited benefit.

Anastasia Constantinidou1, Michael Hofman, Michael O'Doherty, Katharine M Acland, Ciaran Healy, Mark Harries.   

Abstract

Positron emission tomography (PET) is increasingly used for the staging and management of melanoma. The aim of this study was to evaluate the role of PET or PET/ computed tomography (CT) as a routine procedure in patients with positive sentinel node biopsy (SNB). Thirty patients with melanoma of Breslow thickness greater than 1 mm who had PET or PET/CT scans performed within 100 days after a positive SNB were reviewed retrospectively. Two patients (6%) had a positive PET scan, none of which were melanoma related. The first patient had a synchronous neuroendocrine thyroid tumour and the second patient had increased uptake in the chest wall, which proved to be old trauma. Lymph node dissection was positive in five cases (16%). With a median follow-up of 24 months, 21 patients remained disease free. In none of the 30 cases did the early PET scan after a positive SNB alter subsequent melanoma management. The role of PET scanning soon after a positive sentinel node biopsy seems to be of limited benefit. It is questionable whether any imaging is beneficial at this stage. The results of this review suggest that PET scanning might not be indicated for this group of patients.

Entities:  

Mesh:

Year:  2008        PMID: 18227709     DOI: 10.1097/CMR.0b013e3282f62404

Source DB:  PubMed          Journal:  Melanoma Res        ISSN: 0960-8931            Impact factor:   3.599


  6 in total

1.  Targeted melanoma imaging and therapy with radiolabeled alpha-melanocyte stimulating hormone peptide analogues.

Authors:  T Quinn; X Zhang; Y Miao
Journal:  G Ital Dermatol Venereol       Date:  2010-04       Impact factor: 2.011

2.  Ultrasound, CT, MRI, or PET-CT for staging and re-staging of adults with cutaneous melanoma.

Authors:  Jacqueline Dinnes; Lavinia Ferrante di Ruffano; Yemisi Takwoingi; Seau Tak Cheung; Paul Nathan; Rubeta N Matin; Naomi Chuchu; Sue Ann Chan; Alana Durack; Susan E Bayliss; Abha Gulati; Lopa Patel; Clare Davenport; Kathie Godfrey; Manil Subesinghe; Zoe Traill; Jonathan J Deeks; Hywel C Williams
Journal:  Cochrane Database Syst Rev       Date:  2019-07-01

3.  The role of FDG-PET/CT in preoperative staging of sentinel lymph node biopsy-positive melanoma patients.

Authors:  Evan C Frary; Dorte Gad; Lars Bastholt; Søren Hess
Journal:  EJNMMI Res       Date:  2016-10-05       Impact factor: 3.138

4.  Vemurafenib plus cobimetinib in unresectable stage IIIc or stage IV melanoma: response monitoring and resistance prediction with positron emission tomography and tumor characteristics (REPOSIT): study protocol of a phase II, open-label, multicenter study.

Authors:  Bernies van der Hiel; John B A G Haanen; Marcel P M Stokkel; Daniel S Peeper; Connie R Jimenez; Jos H Beijnen; Bart A van de Wiel; Ronald Boellaard; Alfons J M van den Eertwegh
Journal:  BMC Cancer       Date:  2017-09-15       Impact factor: 4.430

5.  Usefulness of 18F-FDG PET/CT in Cutaneous Melanoma Patients with Negative Sentinel Lymph Nodes and High Clark Levels.

Authors:  Özge Vural Topuz; Fatma Arzu Görtan; Zübeyde Rana Kaya Döner; Çetin Önsel; Haluk Burçak Sayman
Journal:  Mol Imaging Radionucl Ther       Date:  2018-06-07

6.  Staging 18F-FDG PET/CT influences the treatment plan in melanoma patients with satellite or in-transit metastases.

Authors:  Lodewijka H J Holtkamp; Annette H Chakera; Sebastian Fung; Jonathan R Stretch; Robyn P M Saw; Kenneth Lee; Sydney Ch'ng; Maria Gonzalez; John F Thompson; Louise Emmett; Omgo E Nieweg
Journal:  Melanoma Res       Date:  2020-08       Impact factor: 3.199

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.